Combining Parasite and Vector Components for Development of a Leishmania Vaccine

Period of Performance: 08/31/2016 - 08/30/2018

$444K

Phase 1 SBIR

Recipient Firm

Protein Advances, Inc.
Seattle, WA 98102
Principal Investigator

Abstract

To use sandfly and parasite antigens to develop a visceral leishmaniasis vaccine.